TY  - JOUR
A1  - Halwe, Sandro
A1  - Kupke, Alexandra
A1  - Vanshylla, Kanika
A1  - Liberta, Falk
A1  - Grüll, Henning
A1  - Zehner, Matthias
A1  - Rohde, Cornelius
A1  - Krähling, Verena
A1  - Gellhorn Serra, Michelle
A1  - Kreer, Christoph
A1  - Klüver, Michael
A1  - Sauerhering, Lucie
A1  - Schmidt, Jörg
A1  - Cai, Zheng
A1  - Han, Fei
A1  - Young, David
A1  - Yang, Guangwei
A1  - Widera, Marek
A1  - Koch, Manuel
A1  - Werner, Anke
A1  - Kämper, Lennart
A1  - Becker, Nico
A1  - Marlow, Michael S.
A1  - Eickmann, Markus
A1  - Ciesek, Sandra
A1  - Schiele, Felix
A1  - Klein, Florian
A1  - Becker, Stephan
T1  - Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection
T2  - Viruses
N2  - Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.
KW  - SARS-CoV-2
KW  - monoclonal antibody
KW  - neutralizing antibody
KW  - virus
KW  - animal experiments
KW  - mice
KW  - transduction
KW  - intranasal administration
KW  - topical administration
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62189
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-621896
SN  - 1999-4915
VL  - 13.2021
IS  - 8, art. 1498
SP  - 1
EP  - 21
PB  - MDPI
CY  - Basel
ER  -